Filing Flows › Comparisons › RGEN vs TARS
Repligen vs Tarsus Pharmaceuticals: RGEN and TARS compared
Repligen is the larger company: $209M of revenue in its latest quarter (Q3 2026) against $195M for Tarsus Pharmaceuticals (Q3 2026). Tarsus Pharmaceuticals is growing faster (+64% against +11% a year earlier). Repligen is more profitable, with an operating margin of -14.1% against -340.3%.
Where the money goes: RGEN and TARS
Repligen (RGEN) · Q3 2026
Repligen, Q3 2026: revenue $209M (+11% year over year), operating margin -14.1%, net loss $38.4M, operating cash flow $43.1M. The chart follows the revenue to costs, profit and cash.
Tarsus Pharmaceuticals (TARS) · Q3 2026
Tarsus Pharmaceuticals, Q3 2026: revenue $195M (+64% year over year), operating margin -340.3%, net loss $668M, operating cash flow −$6.0M. The chart follows the revenue to costs, profit and cash.
| Repligen (RGEN) | Tarsus Pharmaceuticals (TARS) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $209M | $195M |
| Revenue growth, Y/Y | +11% | +64% |
| Operating margin | -14.1% | -340.3% |
| Net earnings | −$38.4M | −$668M |
| Net margin | -18.4% | -343.5% |
| Operating cash flow | $43.1M | −$6.0M |
| Free cash flow | $38.2M | — |
| Market value | $9.9B | — |
| Analysts’ mean target | $203.45 | — |
Where the revenue comes from
Repligen
- Product: $209M (100%)
- Royalty and other revenue: $44K (0%)
Questions
Which is bigger, Repligen or Tarsus Pharmaceuticals?
Repligen is the larger company: $209M of revenue in its latest quarter (Q3 2026) against $195M for Tarsus Pharmaceuticals (Q3 2026).
Is Repligen or Tarsus Pharmaceuticals growing faster?
Tarsus Pharmaceuticals is growing faster (+64% against +11% a year earlier).
Which is more profitable, Repligen or Tarsus Pharmaceuticals?
Repligen is more profitable, with an operating margin of -14.1% against -340.3%.
More: Repligen earnings · how Repligen makes money · Tarsus Pharmaceuticals earnings · how Tarsus Pharmaceuticals makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Oct 30, 2026; 10-Q filed Nov 3, 2026). Fiscal quarters can end on different dates. Not investment advice.